荟萃分析:炎症性肠病治疗中先进疗法的持续用药情况
该系统综述纳入截至2023年3月的63项观察性研究,评估多种先进疗法在溃疡性结肠炎(UC)和克罗恩病(CD)中的持续用药率。维得利珠单抗在UC中1年持续率最高(73.8%,95%CI:70.0%-77.6%),乌司奴单抗在CD中最高(77.5%,95%CI:72.9%-82.1%)。与TNF抑制剂相比,维得利珠单抗在UC和CD中1年持续率均更高,乌司奴单抗在CD中1年持续率更高。
要点
- 维得利珠单抗在UC中1年持续率为73.8%(95%CI:70.0%-77.6%),为各药最高。
- 乌司奴单抗在CD中1年持续率为77.5%(95%CI:72.9%-82.1%),为各药最高。
- 与TNFi相比,维得利珠单抗UC 1年RR=1.30(95%CI:1.19-1.41),CD 1年RR=1.14(95%CI:1.09-1.20);乌司奴单抗CD 1年RR=1.15(95%CI:1.07-1.23);维得利珠单抗UC 2年RR=1.33(95%CI:1.14-1.54)。
核心结论
- 本荟萃分析显示乌司奴单抗和维得利珠单抗的持续用药优于TNFi,为临床医生在UC和CD治疗选择中提供参考。
研究设计与样本
- 系统综述纳入截至2023年3月的观察性研究,共63项,评估先进疗法在UC和CD中的持续用药情况。
- 考察的先进疗法包括英夫利西单抗、阿达木单抗、维得利珠单抗、乌司奴单抗、戈利木单抗、赛妥珠单抗和托法替布。
- 合并各药物的持续率,并开展荟萃分析比较新型药物与传统TNF抑制剂(TNFi,即英夫利西单抗和阿达木单抗)的持续率。
主要发现
- 在UC中,维得利珠单抗的1年持续率最高,为73.8%(95%CI:70.0%-77.6%)。
- 在CD中,乌司奴单抗的1年持续率最高,为77.5%(95%CI:72.9%-82.1%)。
- 与TNFi相比,维得利珠单抗1年持续率在UC中RR为1.30(95%CI:1.19-1.41),在CD中RR为1.14(95%CI:1.09-1.20)。
- 与TNFi相比,乌司奴单抗在CD中1年持续率RR为1.15(95%CI:1.07-1.23)。
- 与TNFi相比,维得利珠单抗在UC中2年持续率RR为1.33(95%CI:1.14-1.54)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges in treatment selection. Persistence analysis assesses drug durability in real-world settings, acting as a surrogate marker for medication efficacy and tolerance. Unlike traditional comparative studies, persistence analysis provides insights extending beyond the initial year of treatment. AIM: To provide real-world evidence on treatment effectiveness, tolerability and preferences of physicians and patients regarding various advanced therapies for IBD. METHODS: We conducted a systematic review of observational studies up to March 2023 assessing advanced therapies' persistence in UC and CD. Advanced therapies under examination included infliximab, adalimumab, vedolizumab, ustekinumab, golimumab, certolizumab and tofacitinib. We pooled the persistence of each agent and conducted a meta-analysis to compare the persistence of newer agents with traditional TNF inhibitors (TNFi)-specifically infliximab and adalimumab. RESULTS: Among 63 observational studies, vedolizumab had the highest 1-year persistence in UC (73.8%, 95% CI: 70.0%-77.6%) and ustekinumab in CD (77.5%, 95% CI: 72.9%-82.1%). Compared to TNFi, vedolizumab demonstrated increased persistence with a relative risk (RR) of 1.30 (95% CI: 1.19-1.41) for UC and 1.14 (95% CI: 1.09-1.20) for CD at 1 year, while ustekinumab demonstrated a RR of 1.15 (95% CI: 1.07-1.23) for CD at 1 year. Vedolizumab exhibited sustained increased persistence in UC over 2 years compared to TNFi (RR: 1.33, 95% CI 1.14-1.54). CONCLUSION: This meta-analysis highlights the superior persistence of ustekinumab and vedolizumab over TNFi, and offers valuable insights for clinicians navigating the challenging landscape of UC and CD therapeutic choices.
引用
- Yiu TH, Ko Y, Pudipeddi A, et al. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2024. PMID: 38651771. doi:10.1111/apt.18006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。